SCHEMBL17570950

SCHEMBL17570950

COC(=O)CCCCC(=O)NCC(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.66
TSHR P16473 3/20 0.53
FAAH O00519 6/20 0.49
GAA P10253 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
PTPN1 P18031 1/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
APEX1 P27695 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
GPR18 Q14330 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22987343 1.00 RECQL (0.66) RECQLTSHRFAAHGAAMEN1
SCHEMBL31336136 0.87 RECQL (0.81) RECQLTSHRFAAHGAAMEN1
SCHEMBL30838573 0.87 RECQL (0.81) RECQLTSHRFAAHGAAMEN1
SCHEMBL30838583 0.87 RECQL (0.81) RECQLTSHRFAAHGAAMEN1
SCHEMBL30838584 0.87 RECQL (0.81) RECQLTSHRFAAHGAAMEN1
SCHEMBL25908042 0.85 RECQL (0.66) RECQLTSHRFAAHGAAMEN1
SCHEMBL13286460 0.84 RECQL (0.57) RECQLTSHRFAAHGAAMEN1
SCHEMBL22064151 0.84 RECQL (0.63) RECQLTSHRFAAHGAAMEN1
SCHEMBL8466257 0.82 ALDH1A1 (0.58) RECQLTSHRFAAHGAAMEN1
SCHEMBL24753945 0.82 PTPN1 (0.52) RECQLTSHRFAAHGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 US disclosed
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 US disclosed
US-11116845-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2021-09-14 US disclosed
EP-3778601-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES ImmunoGen, Inc. (US) 2021-02-17 EP disclosed
US-20200405870-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2020-12-31 US disclosed
US-10722588-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2020-07-28 US disclosed
EP-3189056-B1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN INC (US) 2020-06-10 EP disclosed
US-20190269786-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2019-09-05 US disclosed
US-10238751-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2019-03-26 US disclosed
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-11-30 US disclosed
US-9669102-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2017-06-06 US disclosed
US-20160082114-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2016-03-24 US disclosed
WO-2016036801-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. (US) 2016-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10238751-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-11116845-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-20200405870-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-20160082114-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-10722588-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-20190269786-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885TSHR 889/4885FAAH 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.